⏳ Fetching live dividend data...
Home › Calculator › MPSYF Dividend Calculator 2026
MorphoSys AG · OTC
Price: $73.27 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
MPSYF is not a dividend-focused stock
MPSYF pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
MorphoSys AG (MPSYF) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling cancer and autoimmune diseases. Among its key offerings is Tafasitamab, an antibody therapy approved for treating specific B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also boasts a robust pipeline, with several promising candidates under development. These include Pelabresib, a small molecule currently in Phase II clinical trials for myelofibrosis, and Felzartamab, a CD38-targeting antibody undergoing Phase I/II investigation for anti-PLA2R-positive membranous nephropathy, an autoimmune kidney disorder. Additionally, MorphoSys is developing CPI-0209, a small molecule in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. Beyond its proprietary projects, MorphoSys collaborates with pharmaceutical partners on other therapeutic programs. These include Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis, psoriatic arthritis, and palmoplantar pustulosis, and MOR210/TJ210 targeting immuno-oncology and autoimmune conditions. The company has forged several strategic alliances to further its mission. Notable partnerships include a regional licensing agreement with I-Mab Biopharma for the development and commercialization of felzartamab across China, Taiwan, Hong Kong, and Macau, as well as a strategic alliance with LEO Pharma. Furthermore, MorphoSys has a joint collaboration and licensing pact with Incyte Corporation for the development and market introduction of tafasitamab. It also participates in a clinical collaboration with Incyte Corporation and Xencor, Inc. to evaluate a combination therapy of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Established in 1992, MorphoSys AG maintains its headquarters in Planegg, Germany.
No. MorphoSys AG (MPSYF) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. MPSYF has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MPSYF position with:
Real after-tax yield depends on where you live and how you hold MPSYF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
MPSYF pays quarterly — 4 times per year. Ex-div: —.
How MPSYF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MPSYF sourced from FMP /financial-growth endpoint — real data, not estimates.
Compare MPSYF with peers: MPSYF vs ARHCF · MPSYF vs ASPHF · MPSYF vs BIESF
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MPSYF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
MorphoSys AG (MPSYF) is currently trading at $73.27, trading near its 52-week high. It does not currently pay a regular dividend.
MorphoSys AG (MPSYF) is a healthcare stock trading at $73.27. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever